Optina Diagnostics

Optina Diagnostics is pioneering the development of a groundbreaking tool designed to identify beta amyloid AB plaques, which are crucial biomarkers for Alzheimer's disease. The company operates in the healthcare diagnostics market, focusing on early detection of neurodegenerative diseases through non-invasive eye scans. Optina Diagnostics primarily serves healthcare providers, research institutions, and clinical study organizations. The business model revolves around selling and licensing its diagnostic technology to these clients, generating revenue through product sales, service agreements, and collaborative research projects. By leveraging advanced imaging techniques and artificial intelligence, Optina Diagnostics aims to revolutionize the early diagnosis of Alzheimer's, potentially altering the course of treatment and management for millions of patients worldwide. The company is also actively involved in community patient access programs to broaden the reach of its diagnostic solutions.

Keywords: Alzheimer's, beta amyloid, eye scan, diagnostics, healthcare, neurodegenerative, imaging, artificial intelligence, early detection, biomarkers.